IO Biotech, Inc. · OTC:IOBTQ

IO Biotech — Jefferies Healthcare Conference November 2025

28 slides from IO Biotech's conference presentation, Nov 18, 2025

  1. Slide 1: Breaking Boundaries. Igniting Change.

    Breaking Boundaries. Igniting Change. Nasdaq: IOBT Jefferies Healthcare Conference November 2025 Exhibit 99.1

  2. Slide 2: Disclaimer | Forward Looking Statements

    DISCLAIMER | Forward Looking Statements Certain information contained in this presentation includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our business pl

  3. Slide 3: Cylembio is an investigational drug candidate not approved by FDA

    Cylembio is an investigational drug candidate that has not been approved for marketing by the US FDA or other regulatory authorities.

  4. Slide 4: IO Biotech | Breaking boundaries. Igniting change

    IO Biotech | Breaking boundaries. Igniting change PHASE 3 RESULTS *Statistical significance threshold for this study was p≤0.045. 1. https://gco.iarc.fr/today/en/; 2. https://seer.cancer.gov/statfacts/html/melan.html; 3. Melanoma Research Alliance; 4. Larkin et al. N Engl J Med 2019;381:1535-1546; 5

  5. Slide 5: The Melanoma Patient Journey

    1. Melanoma of the Skin — Cancer Stat Facts; 2. https://seer.cancer.gov/statfacts/html/melan.html; Bajaj. J Natl Cancer Inst. 2020; Leeneman. EJC. 2021; Zhang. Adv Ther. 2023; Eggermont. J of Clin Onc. 2019; Eggermont. NEJM. 2022; Wolchok. J Clin Oncol. 2022; Miller, CA Cancer J Clin, 2019; National

  6. Slide 6: Cylembio in First-Line Advanced Melanoma

    Cylembio in First-Line Advanced Melanoma

  7. Slide 7: Phase 3 trial design

    Primary endpoint PFS by central review Secondary/exploratory endpoints ORR, DRR, CRR, OS, DoR, TTR, DCR Incidence of AEs and SAEs Quality of life Biomarkers in blood and tumor tissue will also be assessed Stratification Endpoints Randomization 407 enrolled across >100 sites in Europe, Australia, Sou

  8. Slide 8: Cylembio demonstrated PFS improvement across virtually all subgroups

    PHASE 3 TRIAL | Cylembio demonstrated PFS improvement across virtually all pre-specified subgroups and stratification factors Topline results released August 2025 *Statistical significance threshold for this study was p≤0.045. **Post-hoc analysis. Source: Data on file. Overall Survival trend favorin

  9. Slide 9: Early Separation of PFS Curves – Widening Over Time

    PHASE 3 TRIAL | Early Separation of PFS Curves at 3 Months – Widening Over Time Source: Company data on file. Kaplan-Meier estimate of PFS in ITT determined by BICR per RECISTv1.1 and stratified by PD-L1 status and disease stage

  10. Slide 10: Trend in Overall Survival Benefiting Cylembio

    PHASE 3 TRIAL | Trend in Overall Survival Benefiting Cylembio (not yet mature) separating early and widening HR, 0.79; 95% CI, 0.57 to 1.10 OS not mature HR 0.79 is in line with 12 month OS data reported from other IO combinations Source: Company data on file. Kaplan–Meier estimate of OS in ITT and

  11. Slide 11: Safety Data

    SAFETY DATA | Treatment with Cylembio did not add significant systemic toxicity compared to patients treated with pembrolizumab monotherapy Source: Company data on file. Acronyms: AE, adverse event; CTCAE, common terminology criteria for adverse events; MedDRA, medical dictionary for medical regulat

  12. Slide 12: Market Opportunity in Advanced Melanoma

    MARKET OPPORTUNITY IN ADVANCED MELANOMA | Cylembio® profile has potential to fulfill significant unmet needs and drive market leadership 1. https://gco.iarc.fr/today/en/; 2. https://seer.cancer.gov/statfacts/html/melan.html; 3. Melanoma Research Alliance; 4. Larkin et al. N Engl J Med 2019;381:1535-

  13. Slide 13: Cylembio is an ideal combination partner candidate

    Cylembio is an ideal combination partner candidate that we believe could deliver clinical activity without tolerability issues: IO102-IO103 has demonstrated improvement in PFS, trend towards long and durable response including in hard-to-treat subgroups, with favorable safety across a number of comb

  14. Slide 14: Proposed Phase 3 trial design

    Primary endpoint PFS by central review Secondary/exploratory endpoints OS, DoR, TTR, DCR Incidence of AEs and SAEs Quality of life Biomarkers in blood and tumor tissue will also be assessed Stratification Endpoints Phase 2 (step 1) Randomization Advanced melanoma Unresectable stage III Metastatic st

  15. Slide 15: Our Pipeline: NSCLC, SCCHN, Neoadjuvant/adjuvant

    Our Pipeline: NSCLC, SCCHN, Neoadjuvant/adjuvant

  16. Slide 16: Pipeline

    Product candidates Line of therapy/ indication Pre-clinical Phase 1 Phase 2 Phase 3 Takeaways & next steps Cylembio® IO102-IO103 Targets: IDO1, PD-L1 IOB-013, IOB-023: First Line Advanced Melanoma* Cylembio demonstrated clinical improvement in PFS, narrowly missed statistical significance in IOB-013

  17. Slide 17: Totality of clinical data in NSCLC, SCCHN and melanoma

    FIRST-LINE METASTATIC NSCLC Results from Phase 2 (SITC 2024) ORR 55% unconfirmed/48% confirmed; mPFS 8.1 months Benchmark** ORR 39%, mPFS 6.5 months Status Encouraging ORR and PFS and no progression in nearly half of patients FIRST-LINE RECURRENT/ METASTATIC SCCHN Results from Phase 2 (ESMO 2024) OR

  18. Slide 18: Addressable Patients

    ADDRESSABLE PATIENTS | Cylembio with potential to redefine treatment of hard-to-treat solid tumors and expanding beyond 1L advanced melanoma Total addressable patients (US) >100,000 patients1 ~40,000 patients2 ~15,000 patients3 Expand to earlier lines 3 Peri-operative SCCHN Peri-operative melanoma A

  19. Slide 19: Platform Potential

    PLATFORM POTENTIAL | The proposed adaptive Phase 3 trial aims to give IOBT the potential to jump ahead with the goal of becoming the first triple combination therapy New proposed Phase 3 study (IOB-023) Designed to be well positioned in evolving/future landscape (SoC) Goal is to demonstrate long/dur

  20. Slide 20: Pre-clinical pipeline: Arginase 1 and TGFβ programs

    T-win platform can be used outside oncology with opportunity to investigate infectious diseases Two preclinical programs in solid tumors showing evidence of anti-tumor activity as monotherapy or in combination PRE-CLINICAL PIPELINE | Expanding the clinical portfolio with Arginase 1 program; IND fili

  21. Slide 21: Our T-win Platform

    win® Platform OurT (6)

  22. Slide 22: Mechanism of Action

    MECHANISM OF ACTION | IO Biotech’s T-win® vaccine approach supported by improvement in PFS demonstrated with Cylembio in IOB-013* Subcutaneous injection with T-win® therapeutic cancer vaccine T-win vaccine activates T cells with a dual mechanism of action T cells attack both target expressing tumor

  23. Slide 23: Off-the-Shelf Treatment

    OFF-THE-SHELF TREATMENT | Cylembio is designed to ensure patients access to treatment without delay* * Compared to a personalized vaccine ** E.g., anti PD-1 treatment Characteristics of an off-the-shelf vaccine enhancing patients and physicians’ experience Directly available… at site of care, in bot

  24. Slide 24: Outlook

    Outlook (6)

  25. Slide 25: Milestones

    MILESTONES | Several important milestones expected through 2026 Cylembio | 1L Advanced Melanoma Top-line readout of primary endpoint in phase 3 study, 3Q25, narrowly missed statistical significance Enrollment completed in January 2025 Initial data from neoadjuvant/adjuvant Ph2 available 2H25; presen

  26. Slide 26: IO Biotech Team

    IO Biotech Team (6)

  27. Slide 27: The Team

    THE TEAM | We have a strong management team with large biopharma and biotech experience Mai-Britt Zocca, PhD President and Chief Executive Officer Amy Sullivan, MBA Chief Financial Officer Dan Mannix, PhD SVP Regulatory Devin Smith General Counsel Qasim Ahmad, MD Chief Medical Officer Faiçal Miyara,

  28. Slide 28: Board of Directors and Scientific Advisory Board

    THE TEAM | Our management team is supported by the Board of Directors and the Scientific Advisory Board Peter Hirth, Ph.D. Chairman Kathleen Sereda Glaub, M.B.A. Member Christian Elling, Ph.D. Member – Lundbeckfonden Heidi Hunter Member David V. Smith, M.B.A. Member Mai-Britt Zocca, Ph.D. Founder, P

IO Biotech — Jefferies Healthcare Conference November 2025 on 6ix